| INTRODUC TI ON
Hypertension is a major risk factor for cardiovascular disease and other age-related conditions, such as dementia and chronic kidney disease, worldwide. Strict blood pressure (BP) control is one of the most effective approaches to prevent cardiovascular events. [1] [2] [3] Recently released 2017 American Heart Association (AHA)/ American College of Cardiology (ACC) guidelines lowered thresholds for the diagnosis and management of hypertension from 140/90 to 130/80 mm Hg. 4 This new threshold may be particularly relevant in Asia due to the different characteristics of hypertension and related cardiovascular disease in Asians. [5] [6] [7] Stroke and non-ischemic heart failure, both of which are closely related to hypertension, are more common in Asia than in Western countries. 5, 7 The BP-associated slope of cardiovascular events, especially stroke, is steeper in Asia than in Westerners. 8 Thus, the benefits associated with strict BP control should be even greater in Asia. 5, [8] [9] [10] Out-of-clinic measurement of BP using ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM) is now recommended for the management of hypertension. [11] [12] [13] [14] This is because ambulatory or home BP measurements are more closely associated with cardiovascular event risk and organ damage than clinic BP. 4, 13, 15, 16 Again, this is likely to be of greater importance in Asia due to the presence of Asian-specific characteristics in the 24-hour BP profile. 5, [17] [18] [19] In addition, the prevalence of masked uncontrolled hypertension (normotensive for clinic BP and hypertension based on out-of-office BP), excessive morning BP surge and morning hypertension, and nocturnal hypertension is higher in Asians than in Westerners. 17, [20] [21] [22] [23] [24] A self-measured home BP-guided strategy has been stressed as the most effective practical approach of the management of hypertension in Asia. 13, [25] [26] [27] There are several studies highlighting the importance of home BP for improving cardiovascular prognosis. [28] [29] [30] [31] [32] [33] However, the findings of some of these studies are limited due to a lack of standardization in the BP measurement schedule, BP measurement device, and recording of home BP measurements, as well as a lack of measurement of nocturnal BP, which is an emerging important cardiovascular risk factor. In addition, all the home BP data in these studies were obtained at least 5 years ago and may not reflect the current status of home BP. Given that guidelinedriven antihypertensive medication with a lower home BP target (<135/85 mm Hg) has been widely introduced in Asian hypertension specialist centers over the last 10 years, home BP control status in Asia might now be quite different. However, there are no recent studies looking at home BP control status, and none have employed the same BP measurement schedule using the same validated HBPM device with data memory.
We have recently established the Hypertension, brain, cardiovascular and renal Outcome Prevention and Evidence in Asia (HOPE Asia)
Network to improve management of hypertension and organ protection for "zero" cardiovascular events in Asia. The HOPE Asia Network has three key initiatives: (a) to understand the current evidence; (b) to achieve consensus; and (c) to conduct clinical studies on the current status. 34 As part of the last initiative, the Asia BP@Home study was designed to investigate the current 2017-2018 home BP control status in 11 Asian countries/regions using standardized home BP measurements taken with the same validated HBPM device with data memory.
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2 | ME THODS
| Study design
The Asia BP@Home study design has been described in detail previously. 35 In brief, the study was a prospective, multicenter, non-interventional trial designed to collect home BP data from outpatients living in Asian countries and regions. All patients provided written informed consent before study enrollment, and the study protocol was approved by independent ethics committees or institutional review boards for every study center. All procedures were conducted in accordance with the ethical principles of the Declaration of Helsinki. The study was registered on the ClinicalTrials.gov website (NCT03096119). 
| Study participants

| BP measurements
Patients were provided with the same validated automatic, oscillometric HBPM device (Omron HEM-7130-AP or HEM-7131-E; Omron
Healthcare, Kyoto, Japan) 36 and instructed to measure their BP at home for at least 7 days during a 15-day HBPM period. Patients were asked not to change their medication during the monitoring period.
To avoid reporting bias, BP data were automatically stored in device memory, then entered into the study database by a physician or nurse.
Home BP measurements were performed according to the Expert Panel Consensus Recommendations for HBPM (the HOPE Asia Network), 26, 27 which modified guidelines from the European Society of Hypertension (ESH), 11, 12 Japanese Society of Hypertension (JSH), 13 and the Korean Society of Hypertension, 37 and the China consensus document on HBPM. 38 Clinic BP was measured twice at the first and second (if applicable) study visit.
| Definition of hypertension control subgroups
Definition was based on the morning home SBP measured by HBPM and clinic SBP. Using the clinic 140 mm Hg and morning home 135 mm Hg SBP thresholds, the proportion of patients with wellcontrolled, white-coat, masked uncontrolled, and sustained morning hypertension was determined. We also defined this classification using the new 2017 ACC/AHA guideline thresholds of 130 mm Hg for morning and clinic BP.
| Day-to-day home BP variability
We calculated coefficient of variation (CV) for morning home SBP based on the patients' home BP readings during the study period.
Average real variability (ARV) is the average absolute difference between successive BP measurements and, in contrast to CV, takes the order of the BP measurements into account. Both CV and ARV are partially dependent on the overall mean BP levels over time, and this issue may not be resolved even if mean BP level over time is used as an adjustment factor. Therefore, we used BP variability independent of the mean (VIM), another BP variability measure that has no correlation with mean BP levels. These variability measures have been used in previously reported BP variability studies. 
| Statistical analyses
All statistical analyses were performed using SAS version 9. to obtain the distribution, overall and by hypertension subtype.
| RE SULTS
| Patient demographics and characteristics
A total of 1467 patients with medicated hypertension from 15 hypertension specialist centers in 11 countries/regions were recruited. Of these, 1443 were included in the analysis ( Figure S1) other antihypertensive drug classes were used by less than 10% of patients (Table 1) . Amlodipine was the most commonly used CCB (48.8% of the total population, 73.9% of all CCBs).
Using the clinic 140 mm Hg and morning home 135 mm Hg SBP thresholds, the proportion of patients with well-controlled hypertension (46%) was higher than that for uncontrolled sustained (22%), white-coat (23%), and masked uncontrolled (9%) hypertension.
Corresponding values calculated using the 2017 ACC/AHA guideline thresholds of 130 mm Hg for morning and clinic BP were 26% of patients with well-controlled hypertension and 40%, 28%, and 6%, respectively, with uncontrolled sustained, white-coat or masked uncontrolled hypertension. was highest (45.6%) when control was classified using the clinic SBP 
| Home BP control status
| Country/region difference
There were significant country/region differences in the demographics of study participants (Table S1 ) and home BP control status. However, the prevalence of controlled hypertension was higher than that of white-coat, masked uncontrolled or uncontrolled The prevalence of well-controlled morning home SBP (well-controlled hypertension plus white-coat hypertension) was higher than that of uncontrolled morning home SBP (masked uncontrolled hypertension plus uncontrolled hypertension) in 13/15 centers using the higher thresholds ( Figure 2A ) and in 11/15 centers using the new, lower thresholds ( Figure 2B ). 2) of the J-HOP study 39 was seen more often in this study ( Figure 3D ). In addition, more than 25% of patients were in the highest quartile for BP variability at 13/15 centers (the exceptions were India and Japan) ( Figure 3D ).
| D ISCUSS I ON
The Asia BP@Home study is the first Asian simultaneous cross-sectional study on home BP control status in major hypertension spe- In addition, there were significant country/regional differences in home BP control status and the degree of home BP variability.
In the 2017 ACC/AHA guidelines compared with other or previous documents, the office SBP target has decreased by 10 mm Hg lower (SBP <140 mm Hg to <130 mm Hg) and the home SBP target is 5 mm Hg lower (SBP <135 mm Hg to <130 mm Hg).
Needless to say, this will make uncontrolled hypertension more common while fewer patients will have controlled hypertension.
Similarly, white-coat effect will be found more often because some patients previously classified as having controlled hypertension will now be defined as having white-coat effect, while masked uncontrolled hypertension should be found less often because many of these patients will now fit the criteria for uncontrolled hypertension (although some controlled hypertension will become masked uncontrolled hypertension). antihypertensive agent in the Asia BP@Home study was the longacting CCB, amlodipine (used by 48.8% of patients). The BP-lowering effect of amlodipine persists for 24 hours and is not affected by salt sensitivity and salt intake, although it is dependent on baseline BP. 45, 46 Thus, amlodipine is an appropriate choice for Asian hypertensive patients with high salt intake and high salt sensitivity. The use of long-acting, effective antihypertensives could also have contributed to the smaller morning-evening difference in home SBP and DBP seen in the current study compared with J-HOP. 30 Another difference between the Asia BP@Home and J-HOP studies was the setting in which patients were treated. Our study was conducted in hypertension specialist centers (organized by members of HOPE Asia Network), whereas J-HOP patients were managed by general practitioners.
For Asian patients, we recommend measurement of morning BP before taking medication as the first target of a hypertension management strategy. [47] [48] [49] [50] Lifestyle factors in Asia mean that evening BP is difficult to measure before dinner at home, and evening home BP measured at bedtime after dinner is significantly affected by alcohol consumption and bathing, 51 making this approach much less reliable, as has been shown previously. 52 In addition, as highlighted above, there is a good body of data from
Asia showing that morning home BP is an independent predictor of cardiovascular events. 28, 30, 31, 33 The results of the prospective J-HOP study clearly demonstrated that patients with wellcontrolled morning home SBP (<135 mm Hg at baseline) were at lower risk of having a stroke than those with a higher morning home SBP. 30 In addition, the large real-world observational prospective HONEST study of more than 20 000 hypertensive patients receiving olmesartan-based antihypertensive medication
showed that on-treatment morning home SBP <125 mm Hg was associated with a significantly lower rate of both stroke and coronary artery disease events compared with a morning home SBP of ≥145 mm Hg, especially in high-risk patients. 53 Furthermore, the home BP-guided interventional HOMED-BP study demonstrated that achievement of lower home SBP was significantly associated with better cardiovascular prognosis. 28 Considering these results, the well-controlled home BP achieved with specialist management in the Asia BP@Home study was 9.5% of the total sample, almost half the 19% rate found in the J-HOP study. 30 Masked uncontrolled hypertension is an important clinical issue. In the international ABPM registry of hypertensive patients, ARTEMIS, the prevalence of masked uncontrolled hypertension was higher in Asians than in the Westerners. 24 In an analysis of data from the J-HOP study of Japanese patients, the increased stroke risk associated with the presence of masked uncontrolled hypertension was compara- Home BP variability was greater in the Asia BP@Home study with a significant country/regional difference, even though home BP control status was better in the Asia BP@Home vs J-HOP studies.
Differences in environmental factors and lifestyles between counties may contribute to increased home BP variability. In the current study, we used three measures of day-by-day home BP variability (CV, ARB, and VIM) because values in the highest quartiles of these three measures (CV ≥ 6.1, ARV ≥ 8.5, and VIM ≥ 8.2) were significantly associated with stroke prognosis independent of mean home BP in the J-HOP study. 39 Similar findings were reported in other population-based studies, where day-by-day home BP variability was a significant predictor of cardiovascular prognosis independent of the average home BP. 40, 56, 57 The pathological thresholds of day-by-day home BP variability in treated patients with well-controlled average home BP need to be determined in the future prospective studies.
There were significant country/regional differences in home BP control status, and in home BP variability. Rates of uncontrolled hypertension were much higher in some regions, while controlled hypertension was more common in others. These trends were accentuated when the 2017 ACC/AHA thresholds were applied. In addition, there are significant country/regional difference in cardiovascular death rates in Asia. 7 Each county leader of the HOPE Asia Network plans to explore these inter-country differences and their underlying reasons; results will be reported in due course.
This study also has some limitations. Firstly, the sample size in each country/region was small. Secondly, this study may not be directly applicable to routine clinical care in all participating countries. It is also possible that study patients enrolled from specialist hypertension centers, as was the case in this study, may be more motivated than patients treated in general practice or hospital clin-
ics. An important next step is to create a real-world database of outpatients recruited from general practitioners in each country. We did not collect urine or blood samples to confirm adherence to antihypertensive therapy, although we asked patients not to change their medication during the monitoring period. Finally, there is not yet any data on the clinical relevance of the four hypertension phenotype classifications using the lower new thresholds in the 2017 ACC/AHA guidelines. Therefore, the prognosis for hypertension subgroups based on this classification needs to be determined.
| CON CLUS IONS
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